PRINCETON, N.J. --(BUSINESS WIRE)--May 15, 2020-- UroGen Pharma Ltd. (Nasdaq:URGN) today announced the presentation of positive data from the UGN-101 ( Jelmyto™ (mitomycin) for pyelocalyceal solution) Phase 3 OLYMPUS trial in patients with low-grade upper tract urothelial cancer (LG-UTUC).
Received U.S. FDA Approval for Jelmyto™, the First and Only Non-Surgical Treatment for Patients with Low-Grade Upper Tract Urothelial Cancer (LG-UTUC) Jelmyto Launch on Track for June 1, 2020 Reported UGN-102 Phase 2b Trial Interim Data with 65% Complete Response at Three Months and 85% Durability
Conference Call and Webcast Scheduled for Thursday, May 7, 2020 at 8:30 AM ET PRINCETON, N.J. --(BUSINESS WIRE)--May 1, 2020-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients
59% Complete Response in patients with low-grade upper tract urothelial cancer Kaplan-Meier analysis, based on interim data, estimated 12-month durability at 84% Results supported recent U.S. FDA expedited approval of Jelmyto ™ as the first non-surgical treatment for patients with this
Approval Based on Phase 3 Trial Results Showing a Complete Response Rate of 58% Median Duration of Response Has Not Been Reached Therapy Provides an Effective, Kidney-Sparing Option for Patients With This Rare and Difficult-To- Treat Cancer First-in-Class Approval Validates UroGen’s Innovative
Complete Response (CR) Rate of 65% at Three Months Of those with CR, 97% and 85% of Patients Remained Free of Disease at Six and Nine Months Follow-Up, Respectively Detailed Results Presentation to be Shared Virtually via American Urological Association (AUA) in mid-May PRINCETON, N.J.
Experienced Leadership Team with Established Track Record Prepares for Transition to a Commercial Stage Organization NEW YORK --(BUSINESS WIRE)--Mar. 23, 2020-- UroGen Pharma Ltd. (Nasdaq:URGN) a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and
NEW YORK --(BUSINESS WIRE)-- UroGen Pharma Ltd. (Nasdaq:URGN) a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options, today announced the grants of inducement restricted stock units (“RSUs”) to
Prescription Drug User Fee Act (PDUFA) Goal Date of April 18 th for UGN-101 in Patients with Low-Grade Upper Tract Urothelial Cancer (LG UTUC) Experienced Commercial Team Hired and Prepared for Planned UGN-101 Approval and Launch in Q2 Conference Call and Webcast to be held Today at 8:30 AM ET NEW
NEW YORK --(BUSINESS WIRE)--Feb. 25, 2020-- UroGen Pharma Ltd. (Nasdaq:URGN) a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options, today announced that it will participate in fireside chats at
